Sophia Genetics and AstraZeneca Spain to Increase Ovarian Cancer Testing in Spain
The program started in 2022 when AstraZeneca and Sophia Genetics collaborated to deploy HRD testing to five labs throughout the country.
Read MorePosted by Andy Lundin | Feb 7, 2024 | Unknown Origin & Other Cancer Types |
The program started in 2022 when AstraZeneca and Sophia Genetics collaborated to deploy HRD testing to five labs throughout the country.
Read MorePosted by Andy Lundin | Feb 6, 2024 | Molecular Diagnostics |
Researchers developed a system that allows for same-day analysis of genetic mutations to get results faster, and easier than current methods.
Read MorePosted by Andy Lundin | Feb 1, 2024 | Company News |
Myriad Genetics completed the acquisition of select assets from Intermountain Precision Genomics’ laboratory business.
Read MorePosted by Andy Lundin | Jan 31, 2024 | Cancer |
The genetic test evaluates specific genes that offer individuals insights into their genetic profiles and their effects on health and aging.
Read MorePosted by Andy Lundin | Jan 30, 2024 | Leukemia |
A pilot study proposes a promising clinically applicable genomic assay for the diagnosis of a heterogeneous pediatric leukemia.
Read More